Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) – Equities research analysts at B. Riley issued their Q1 2019 earnings per share estimates for shares of Dicerna Pharmaceuticals in a report released on Tuesday, March 12th. B. Riley analyst M. Mamtani anticipates that the biopharmaceutical company will earn ($0.22) per share for the quarter. B. Riley has a “Buy” rating and a $24.00 price target on the stock. B. Riley also issued estimates for Dicerna Pharmaceuticals’ Q2 2019 earnings at ($0.23) EPS, Q3 2019 earnings at ($0.24) EPS, Q4 2019 earnings at ($0.26) EPS, FY2019 earnings at ($0.96) EPS, FY2020 earnings at ($1.48) EPS and FY2021 earnings at ($1.51) EPS.
Get Dicerna Pharmaceuticals alerts:Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.06). Dicerna Pharmaceuticals had a negative return on equity of 65.91% and a negative net margin of 1,438.68%. The business had revenue of $1.54 million for the quarter, compared to analysts’ expectations of $8.38 million.
A number of other research firms have also issued reports on DRNA. Leerink Swann assumed coverage on shares of Dicerna Pharmaceuticals in a report on Tuesday, November 27th. They set an “outperform” rating and a $24.00 target price for the company. BidaskClub raised shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, March 6th. Zacks Investment Research lowered shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday. SunTrust Banks upped their price objective on shares of Dicerna Pharmaceuticals to $26.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Chardan Capital raised shares of Dicerna Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $18.00 price objective for the company in a report on Tuesday, January 22nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $21.78.
Dicerna Pharmaceuticals stock opened at $12.31 on Thursday. Dicerna Pharmaceuticals has a 52-week low of $8.71 and a 52-week high of $17.98. The firm has a market cap of $720.16 million, a PE ratio of -10.26 and a beta of 2.40.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Dicerna Pharmaceuticals by 512.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,459 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 2,894 shares during the period. Legal & General Group Plc grew its holdings in shares of Dicerna Pharmaceuticals by 38.7% in the fourth quarter. Legal & General Group Plc now owns 9,186 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 2,561 shares during the period. Bank of America Corp DE grew its holdings in shares of Dicerna Pharmaceuticals by 30.3% in the fourth quarter. Bank of America Corp DE now owns 10,596 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 2,465 shares during the period. TD Asset Management Inc. purchased a new stake in shares of Dicerna Pharmaceuticals in the fourth quarter valued at about $169,000. Finally, State Board of Administration of Florida Retirement System grew its holdings in shares of Dicerna Pharmaceuticals by 19.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 18,234 shares of the biopharmaceutical company’s stock valued at $195,000 after purchasing an additional 3,024 shares during the period. 92.81% of the stock is owned by hedge funds and other institutional investors.
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.
See Also: Gap Up Stocks
No comments:
Post a Comment